Fig. 3 | Signal Transduction and Targeted Therapy

Fig. 3

From: Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trial

Fig. 3

Tumor Response of KIF5B or CCDC6-RET Fusion. a Waterfall plots of best percent change from baseline in the sum of longest diameters of target lesions in patients with a KIF5B or CCDC6-RET fusion. b Swimmer plot according to dose level and RET-fusion type. Best response is evaluated as per RECIST 1.1. CCDC6 coiled-coil domain-containing protein 6, KIF5B kinesin family member 5B, NE not evaluable, NSCLC non-small-cell lung cancer, PD progressive disease, PR partial response, RET rearranged during transfection, SD stable disease

Back to article page